Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hassan Website

Raffit Hassan, M.D.

Selected Publications

1)  Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
A novel nomogram for peritoneal mesothelioma predicts survival.
Ann. Surg. Oncol. 20: 555-61, 2013.
[Journal]
2)  Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Mol. Cancer Ther. 12: 48-57, 2013.
[Journal]
3)  Thomas A, Maltzman J, Hassan R.
Farletuzumab in lung cancer.
Lung Cancer. 80: 15-8, 2013.
[Journal]
4)  Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R.
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.
Am. J. Pathol. 182: 1065-77, 2013.
[Journal]
5)  Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Eiden JE, Jaffee EM, Laheru DA.
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.
Clin. Cancer Res. 18: 858-68, 2012.
[Journal]
6)  Miller AC, Hassan R.
Clinical and pathological features are still the best determinants of prognosis in mesothelioma.
Oncology (Williston Park, N.Y.). 26: 1176, 1178, 1180, 2012.
[Journal]
7)  Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP.
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
PLoS ONE. 7: e31507, 2012.
[Journal]
8)  Kalra N, Zhang J, Yu Y, Ho M, Merino M, Cao L, Hassan R.
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Int J Cancer. [Epub ahead of print], 2012.
[Journal]
9)  Thomas A, Hassan R.
Immunotherapies for non-small-cell lung cancer and mesothelioma.
Lancet Oncol. 13: e301-10, 2012.
[Journal]
10)  Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R.
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
Anticancer Res. 32: 5151-8, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/11/2013.